An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs CPI 613 (Primary)
- Indications Acute myeloid leukaemia; Burkitt's lymphoma; Cutaneous T cell lymphoma; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions
- 07 Oct 2014 According to a Cornerstone Pharmaceuticals media release, data was published in Clinical Cancer Research: the official journal of the AACR 2014 and presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 25 Sep 2013 Status changed from active, no longer recruiting to completed, according to a Cornerstone Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History